These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1724998)

  • 1. The antiarrhythmic and antifibrillatory effects of calcium antagonists.
    Billman GE
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S107-17. PubMed ID: 1724998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation.
    Billman GE; Hamlin RL
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1517-26. PubMed ID: 8667218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ischemic disorders of cardiac rhythm: effects of the autonomic nervous system on electrophysiologic findings and pharmacotherapy].
    Gülker H; Thale J
    Z Kardiol; 1986; 75 Suppl 5():15-34. PubMed ID: 3825228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of calcium channel antagonists on cocaine-induced malignant arrhythmias: protection against ventricular fibrillation.
    Billman GE
    J Pharmacol Exp Ther; 1993 Jul; 266(1):407-16. PubMed ID: 8331569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium antagonists, ventricular arrhythmias, and sudden cardiac death: a major challenge for the future.
    Opie LH
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S81-6. PubMed ID: 1725011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-arrhythmia effects of calcium antagonists].
    Gülker H; Ketteler T
    Z Kardiol; 1989; 78 Suppl 5():49-54. PubMed ID: 2698564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
    Aupetit JF; Bui-Xuan B; Kioueh I; Loufoua J; Frassati D; Timour Q
    Can J Physiol Pharmacol; 2000 Mar; 78(3):208-16. PubMed ID: 10721812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of calcium channel antagonists on susceptibility to sudden cardiac death: protection from ventricular fibrillation.
    Billman GE
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1334-42. PubMed ID: 2467981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cocaine: a review of its toxic actions on cardiac function.
    Billman GE
    Crit Rev Toxicol; 1995; 25(2):113-32. PubMed ID: 7612173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention by calcium antagonists of profibrillatory effects of class I antiarrhythmic drugs in acute myocardial ischemia: study in pig heart in situ.
    Bui-Xuan B; Aupetit JF; Freysz M; Faucon G; Timour Q
    Pharmacotherapy; 1997; 17(4):737-45. PubMed ID: 9250551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of calcium in arrhythmogenesis.
    Levy MN
    Circulation; 1989 Dec; 80(6 Suppl):IV23-30. PubMed ID: 2688982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium antagonists and acute myocardial ischemia: comparative effects of gallopamil and nifedipine on ischemia-induced and reperfusion-induced ventricular arrhythmias, epicardial conduction times, and ventricular fibrillation thresholds.
    Gülker H; Haverkamp W; Hindricks G; Bender F
    Cardiovasc Drugs Ther; 1987 Dec; 1(4):367-76. PubMed ID: 3154673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative studies on the anti-arrhythmic and anti-fibrillatory effectiveness of verapamil and nifedipine following acute coronary artery occlusion and reperfusion].
    Gülker H; Thale J; Brisse B; Bender F
    Z Kardiol; 1984 Aug; 73(8):515-24. PubMed ID: 6495811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verapamil in cardiac arrhythmias: an overview.
    Vohra J
    Clin Exp Pharmacol Physiol Suppl; 1982; 6():129-34. PubMed ID: 6749351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ion channels and arrhythmias].
    Borchard U; Hafner D
    Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
    Anderson JL
    Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists.
    Apostolakos MJ; Varon ME
    New Horiz; 1996 Feb; 4(1):45-57. PubMed ID: 8689275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ionic mechanisms of ischemia-related ventricular arrhythmias.
    Ducceschi V; Di Micco G; Sarubbi B; Russo B; Santangelo L; Iacono A
    Clin Cardiol; 1996 Apr; 19(4):325-31. PubMed ID: 8706374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of calcium channel blockers in the prevention of ventricular fibrillation of ischemic etiology: experimental arguments].
    Timour Q; Freysz M; Aupetit JF; Loufoua J; Frassati D; Faucon G
    Bull Acad Natl Med; 1996 Jan; 180(1):215-26; discussion 226-7. PubMed ID: 8696877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy.
    Billman GE
    Pharmacol Ther; 2008 Oct; 120(1):54-70. PubMed ID: 18708091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.